By Christy Santhosh and Kamal Choudhury (Reuters) -Abbott missed analysts' third-quarter revenue estimates on Wednesday, as weakness in its diagnostics and nutrition businesses outweighed robust demand for its medical devices. The company had flagged volatility in the businesses as it navigates a sharp decline in COVID-19 testing demand, new U.S. tariffs, and a freeze on foreign aid by President Donald Trump's administration. The diagnostics division is also facing pricing pressure from China's procurem ...

Abbott reported higher quarterly revenue on Wednesday, driven by strong demand for its medical devices including continuous glucose monitors and heart devices. ...